These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34080290)

  • 21. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
    Weichert W; Denkert C; Schmidt M; Gekeler V; Wolf G; Köbel M; Dietel M; Hauptmann S
    Br J Cancer; 2004 Feb; 90(4):815-21. PubMed ID: 14970859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
    Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
    Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis.
    Wu S; Wu D; Pan Y; Liu H; Shao Z; Wang M
    Pathol Res Pract; 2019 Feb; 215(2):292-301. PubMed ID: 30527357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.
    Ward A; Sivakumar G; Kanjeekal S; Hamm C; Labute BC; Shum D; Hudson JW
    Leuk Lymphoma; 2015 Jul; 56(7):2123-33. PubMed ID: 25347426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-cell analysis identifies PLK1 as a driver of immunosuppressive tumor microenvironment in LUAD.
    Kong Y; Li C; Liu J; Wu S; Zhang M; Allison DB; Hassan F; He D; Wang X; Mao F; Zhang Q; Zhang Y; Li Z; Wang C; Liu X
    PLoS Genet; 2024 Jun; 20(6):e1011309. PubMed ID: 38885192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells.
    Yan L; Zhang Y; Li K; Wang M; Li J; Qi Z; Wu J; Wang Z; Ling L; Liu H; Wu Y; Lu X; Xu L; Zhu Y; Zhang Y
    Pathol Res Pract; 2020 Feb; 216(2):152786. PubMed ID: 31864714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
    de Cárcer G
    Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30862113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.
    Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T
    Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
    Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
    Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of PLKs expression and prognosis in breast cancer.
    Jiawei W; Xiajun B; Tian S; Xuzheng G; Zhenwang Z
    Cancer Genet; 2022 Nov; 268-269():83-92. PubMed ID: 36206661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.
    Kressin M; Fietz D; Becker S; Strebhardt K
    Cells; 2021 May; 10(5):. PubMed ID: 34065956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
    Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
    Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
    J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.
    Singh L; Pushker N; Sen S; Singh MK; Chauhan FA; Kashyap S
    Clin Exp Ophthalmol; 2015 Aug; 43(6):550-7. PubMed ID: 25754767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
    Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
    Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polo-like kinases and acute leukemia.
    Goroshchuk O; Kolosenko I; Vidarsdottir L; Azimi A; Palm-Apergi C
    Oncogene; 2019 Jan; 38(1):1-16. PubMed ID: 30104712
    [TBL] [Abstract][Full Text] [Related]  

  • 40.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.